Search

Your search keyword '"McCoig, Cynthia C"' showing total 13 results
Start Over Author "McCoig, Cynthia C"
13 results on '"McCoig, Cynthia C"'

1. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study

Author

Lowenthal, Elizabeth D, Chapman, Jennifer, Ohrenschall, Rachel, Calabrese, Katherine, Baltrusaitis, Kristin, Heckman, Barbara, Yin, Dwight E, Agwu, Allison L, Harrington, Conn, Van Solingen-Ristea, Rodica M, McCoig, Cynthia C, Adeyeye, Adeola, Kneebone, Jared, Chounta, Vasiliki, Smith-Anderson, Christiana, Camacho-Gonzalez, Andres, D'Angelo, Jessica, Bearden, Allison, Crauwels, Herta, Huang, Jenny, Buisson, Sarah, Milligan, Ryan, Ward, Shawn, Bolton-Moore, Carolyn, Gaur, Aditya H, Best, Brookie M, Capparelli, Edmund V, Hanley, Sherika, Mathiba, Sisinyana Ruth, Naidoo, Megeshinee, Ounchanum, Pradthana, Patel, Faeezah, Paul, Mary E, Townley, Ellen, Vandermeulen, Kati, Whitson, Kyle, and Zabih, Sara

Abstract

Long-acting injectable cabotegravir and rilpivirine have demonstrated safety, acceptability, and efficacy in adults living with HIV-1. The IMPAACT 2017 study (MOCHA study) was the first to use these injectable formulations in adolescents (aged 12–17 years) living with HIV-1. Herein, we report acceptability and tolerability outcomes in cohort 1 of the study.

Published
2024
Full Text
View/download PDF

2. Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

Author

Smith, Graham H R, primary, Henry, W Keith, additional, Podzamczer, Daniel, additional, Masiá, Maria Del Mar, additional, Bettacchi, Christopher J, additional, Arasteh, Keikawus, additional, Jaeger, Hans, additional, Khuong-Josses, Marie-Aude, additional, Montes-Ramírez, Maria Luisa, additional, Stellbrink, Hans-Jürgen, additional, Yazdanpanah, Yazdan, additional, Richmond, Gary J, additional, Sutton, Kenneth C, additional, Zhang, Feifan, additional, McCoig, Cynthia C, additional, St Clair, Marty H, additional, Vandermeulen, Kati, additional, Van Solingen-Ristea, Rodica, additional, Smith, Kimberly Y, additional, Margolis, David A, additional, and Spreen, William R, additional

Published
2021
Full Text
View/download PDF

3. Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With HIV-1 Infection: ~5-Year Results From the LATTE-2 Study

Author

Smith, Graham, Henry, W. Keith, Podzamczer Palter, Daniel, Masiá, Maria Del Mar, Bettacchi, Christopher J., Arasteh, Keikawus, Jaeger, Hans, Khuong-Josses, Marie-Aude, Montes, Maria Luisa, Stellbrink, Hans-jürgen, Yazdanpanah, Yazdan, Richmond, Gary J., Sutton, Kenneth C., Zhang, Feifan, Mccoig, Cynthia C., St. Clair, Marty H., Vandermeulen, Kati, Van Solingen-Ristea, Rodica, Smith, Kimberly Y., Margolis, David A., and Spreen, William R.

Subjects
Immunodeficiència, Nucleòsids, Integrase inhibitors, Inhibidors de la integrasa, Immunodeficiency, Nucleosides
Abstract

Background. In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase 2b study, long-acting (LA) injectable cabotegravir + rilpivirine dosed every 8 weeks (Q8W) or every 4 weeks (Q4W) demonstrated comparable efficacy with daily oral antiretroviral therapy (ART) through 96 weeks in ART-naive adults with human immunodeficiency virus type 1 (HIV-1). Here we report efficacy, tolerability, and safety of cabotegravir + rilpivirine LA over approximately 5 years. Methods. After 20 weeks of oral cabotegravir + abacavir/lamivudine, participants were randomized to cabotegravir + rilpivirine LA Q8W or Q4W or continue oral ART through the 96-week maintenance period. In the extension period through week 256, participants continued their current LA regimen (randomized Q8W/Q4W groups) or switched from oral ART to Q8W or Q4W LA therapy (extension-switch groups). Endpoints assessed included proportion of participants with HIV-1 RNA 1 participant. Conclusions. Cabotegravir + rilpivirine LA exhibited long-term efficacy and tolerability, demonstrating its durability as maintenance therapy for HIV-1 infection.

Published
2021

4. LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials

Author

D'Amico, Ronald, primary, Benn, Paul, additional, McCoig, Cynthia C, additional, Griffith, Sandy, additional, Hudson, Krischan J, additional, Sutton, Kenneth, additional, Harrington, Conn M, additional, Wu, Sterling, additional, Williams, Will, additional, Hove, Kai S, additional, Martin Espanol, Carlos, additional, Fricker, E Jane, additional, Patel, Parul, additional, and Margolis, David, additional

Published
2020
Full Text
View/download PDF

5. 116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study

Author

Mills, Anthony, primary, Richmond, Gary J, additional, Newman, Cheryl, additional, Osiyemi, Olayemi, additional, Cade, Jerry, additional, Brinson, Cynthia, additional, De Vente, Jerome, additional, Andany, Nisha, additional, Margolis, David, additional, Sutton, Kenneth, additional, Wilches, Viviana, additional, Roberts, Jeremy, additional, McCoig, Cynthia C, additional, Vandermeulen, Kati, additional, and Spreen, William, additional

Published
2020
Full Text
View/download PDF

6. 638. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results

Author

Smith, Graham, primary, Henry, Keith, additional, Podzamczer, Daniel, additional, Masiá, Mar, additional, Bettacchi, Christopher, additional, Arasteh, Keikawus, additional, Jaeger, Hans, additional, Khuong-Josses, Marie-Aude, additional, Sutton, Kenneth, additional, Zhang, Feifan, additional, McCoig, Cynthia C, additional, Vandermeulen, Kati, additional, Van Solingen-Ristea, Rodica, additional, Spreen, William, additional, and Margolis, David, additional

Published
2020
Full Text
View/download PDF

7. 1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies

Author

Teichner, Paula, primary, Wu, Sterling, additional, Zhang, Feifan, additional, Dorey, David, additional, D’Amico, Ronald, additional, Griffith, Sandy, additional, Sutton, Kenneth, additional, McCoig, Cynthia C, additional, Upadhyay, Ojesh R, additional, Polli, Joseph, additional, Margolis, David, additional, Van Solingen-Ristea, Rodica, additional, Vandermeulen, Kati, additional, Spreen, William, additional, and Patel, Parul, additional

Published
2020
Full Text
View/download PDF

8. Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min

Author

Ross, Lisa L., primary, Walker, A. Sarah, additional, Lou, Yu, additional, Tenorio, Allan R., additional, Gibb, Diana M., additional, Double, Julia, additional, Gilks, Charles, additional, McCoig, Cynthia C., additional, Munderi, Paula, additional, Musoro, Godfrey, additional, Kityo, Cissy M., additional, Grosskurth, Heiner, additional, Hakim, James, additional, Mugyenyi, Peter N., additional, Cutrell, Amy, additional, Perger, Teodora, additional, and Shaefer, Mark S., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results